Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis

References

• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;25:1094–1108.
   Web of Science ®Google Scholar
• Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74:1037–1044.
   PubMed Web of Science ®Google Scholar
• Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology. 2014;53:1560–1569.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(Suppl 2):ii124–7.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–637.
   PubMed Web of Science ®Google Scholar
• Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell. 2007;28:730–738.
   PubMed Web of Science ®Google Scholar
• Min X, Ungureanu D, Maxwell S, et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (Tyk2). J Biol Chem. 2015;290:27261–27270.
   PubMed Web of Science ®Google Scholar
• Hammarén HM, Ungureanu D, Grisouard J, et al. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015;112:4642–4647.
   PubMed Web of Science ®Google Scholar
• Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462:1–13.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994;370:151–153.
   PubMed Web of Science ®Google Scholar
• Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270:797–800.
   PubMed Web of Science ®Google Scholar
• Nosaka T, Van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270:800–802.
   PubMed Web of Science ®Google Scholar
• Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science. 1994;266:1042–1045.
   PubMed Web of Science ®Google Scholar
• Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat. 2001;18:255–263.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006;65:1558–1564.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006;65:149–156.
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304–1351.
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–8.
   PubMed Web of Science ®Google Scholar
• Bodenmiller B, Zunder ER, Finck R, et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012;30:858–867.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64:1790–1798.
   PubMed Web of Science ®Google Scholar
• Vahedi G, Kanno Y, Furumoto Y, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature. 2015;520:558–562.
   PubMed Web of Science ®Google Scholar
• Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192–2198.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:992–999.
   PubMed Web of Science ®Google Scholar
• Wang SP, Iwata S, Nakayamada S, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014;73:2213–2215.
   PubMed Web of Science ®Google Scholar
• Onda M, Ghoreschi K, Steward-Tharp S, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014;193:48–55.
   PubMed Web of Science ®Google Scholar
• Yarilina A, Xu K, Chan C, et al. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012;64:3856–3866.
   PubMed Web of Science ®Google Scholar
• Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis. 2011;71:440–447.
   PubMed Web of Science ®Google Scholar
• Boyle DL, Wei N, Singhal AK, et al. The JAK inhibitor tofacitinib suppresses synovial jak1-stat1 signalling in rheumatoid arthritis. Ann Rheum Dis. 2013;72:138.
   Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–878.
   PubMed Web of Science ®Google Scholar
• Borie DC, Larson MJ, Flores MG, et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation. 2005;80:1756–1764.
   PubMed Web of Science ®Google Scholar
• Rousvoal G, Si MS, Lau M, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int. 2006;19:1014–1021.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP- 690,550). J Immunol. 2011;186:4234–4243.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63:1150–1158.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895–1905.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–629.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970–981.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507. (Oral-Solo).
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–60. (Oral-Step).
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19. (Oral-Standard).
   PubMed Web of Science ®Google Scholar
• Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–61. (Oral-Sync).
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70. (oral-scan).
   PubMed Web of Science ®Google Scholar
• Sonomoto K, Yamaoka K, Kubo S, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology. 2014;53:914–918.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016 Feb 1;43:504–511. pii: jrheum.150613. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Takeuchi T, Douglas E Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER: 1045
   Google Scholar
• Taylor PC, Keystone EC, Van Der Heijde D, et al. Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER: 2L.
   Google Scholar
• Genovese MC, Kremer JM, Zamani O, et al. Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the Phase 3 RA-BEACON study [abstract OP0029]. Ann Rheum Dis. 2015;74(Suppl. 2):75–76.
   Google Scholar
• Genovese MC, Kremer JM, Kartman C, et al. Previous biologic disease-modifying antirheumatic drug (bDMARD) exposure and efficacy and safety analysis from a phase 3 study of baricitinib in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitors. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER: 1046.
   Google Scholar
• Van Rompaey L, Galien R, Van Der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–3577.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ponce L, Cseuz R, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective as monotherapy in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER: 1049.
   Google Scholar
• Westhovens R, Alten R, Pavlova D, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER: 1048
   Google Scholar
• Hoock T, Hogan J, Mahajan S, et al. VX-509, an orally available Janus kinase 3 (JAK3) specific inhibitor, showed robust activity in pre-clinical models of aberrant immune/inflammatory function. Arthritis Rheum. 2011;63:S443.
   Web of Science ®Google Scholar
• Genovese MC, Van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 Inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46–55.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Inamia M, Ito M, et al. ASP015K: a novel JAK inhibitor demonstrated potent efficacy in adjuvant-induced arthritis model in rats. Arthritis Rheum. 2012;64:S882.
   Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057–1064.
   Google Scholar
• Voss JW, Camp HS, Padley RJ. JAK1 selective inhibitor and uses thereof WO2015061665A1.
   Google Scholar
• Kremer JM, Keystone EC, Emery P, et al. Safety and efficacy of ABT-494, a novel selective JAK1 Inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER: 14L.
   Google Scholar
• Luchi M, Fidelus-Gort RK, Douglas D, et al. A randomized, dose-ranging, placebo-controlled 84-day (12-week) study of INCB039110, a selective Janus kinase-1 inhibitor in patients with active rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl 10):1797.
   Google Scholar
• Luchi M, Fidelus-Gort R, Douglas D, et al. A randomized, dose-ranging, placebo-controlled, 84-day study of INCB039110, a selective Janus kinase-1 inhibitor, in patients with active rheumatoid arthritis. ACR/ARHP Annual Meeting; 2013. ABSTRACT NUMBER: 1797.
   Google Scholar
• Williams WV, Scherle P, Shi J, et al. Initial efficacy of INCB018424, a selective Janus kinase 1& 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). EULAR; 2008. abstract OP-0044.
   Google Scholar
• Winthrop KL, Valdez H, Mortensen E, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:S1051.
   Google Scholar
• Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. J Rheumatol. 2014;41:837–852.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75:831–841.
   Web of Science ®Google Scholar
• Vincenti F, Silva HT, Busque S, et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J Transplant. 2015;15:1644–1653.
   PubMed Web of Science ®Google Scholar